{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T09:10:21Z","timestamp":1748423421927,"version":"3.40.5"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,18]]},"abstract":"<jats:p>Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease. The clinical effectiveness of ursodeoxycholic acid (UDCA) plus glucocorticoids and\/or immunosuppressants remains controversial in PBC patients. The study aimed to compare the efficacy of monotherapy and combination therapy in patients with PBC and to assess the factors affecting the efficacy. In this retrospective study, 266 patients diagnosed with PBC were divided into monotherapy group (UDCA), double therapy group (UDCA plus glucocorticoids or immunosuppressants), and triple therapy group (UDCA plus glucocorticoids and immunosuppressants) according to different treatments. Demographic characteristics, immune parameters, biochemistry profiles, and other indicators were evaluated at baseline, 6 months, and 1 year following treatment. The prognosis was evaluated using the Paris II standard. The liver transplant-free survival at 3, 5, 10, and 15 years was predicted by GLOBE score. All statistical analyses were conducted using SPSS (version 24) software (SPSS Inc, Chicago, IL). The long-term survival rate of the triple therapy group was significantly improved compared with the monotherapy group (<jats:italic toggle=\"yes\">P<\/jats:italic> = .005). In addition, multivariate analysis showed that abnormal platelet count, alkaline phosphatase, and albumin levels were risk factors for poor response. When IgG levels were elevated but below twice the upper limit of normal, the clinical benefit was not significant compared with monotherapy (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; .05). Compared with monotherapy and double therapy, triple therapy may improve the long-term survival rate of PBC patients. Abnormal platelet count, alkaline phosphatase, and albumin levels were associated with a poor prognosis.<\/jats:p>","DOI":"10.1097\/md.0000000000031395","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T22:07:58Z","timestamp":1669846078000},"page":"e31395","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients"],"prefix":"10.1097","volume":"101","author":[{"given":"Zi-Long","family":"Wang","sequence":"first","affiliation":[{"name":"Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Jin","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Hao","sequence":"additional","affiliation":[{"name":"Medical Information Center, Peking University People\u2019s Hospital, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Di","family":"Xie","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Cheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Xiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-6715","authenticated-orcid":false,"given":"Bo","family":"Feng","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1055\/s-0039-1697617","article-title":"The pathogenesis of primary biliary cholangitis: a comprehensive review.","volume":"40","author":"Lleo","year":"2020","journal-title":"Semin Liver Dis"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis.","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment.","volume":"16","author":"Lu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1756284818787400","DOI":"10.1177\/1756284818787400","article-title":"Cholestatic liver diseases: new targets, new therapies.","volume":"11","author":"Santiago","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep.30552","article-title":"Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis.","volume":"70","author":"Honda","year":"2019","journal-title":"Hepatology"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.28932","article-title":"Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.","volume":"65","author":"Samur","year":"2017","journal-title":"Hepatology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases.","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy.","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial.","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"issue":"11\u201312","key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1365-2036.2006.03155.x","article-title":"Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis.","volume":"24","author":"Rautiainen","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J Hepatol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1101\/gr.118042.110","article-title":"Coactivation of GR and NFKB alters the repertoire of their binding sites and target genes.","volume":"21","author":"Rao","year":"2011","journal-title":"Genome Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.dld.2016.03.022","article-title":"Glucocorticoid treatment alters systemic bile acid homeostasis by regulating the biosynthesis and transport of bile salts.","volume":"48","author":"Xiao","year":"2016","journal-title":"Dig Liver Dis"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jhep.2014.03.025","article-title":"Prednisolone increases enterohepatic cycling of bile acids by induction of Asbt and promotes reverse cholesterol transport.","volume":"61","author":"Out","year":"2014","journal-title":"J Hepatol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cld.2018.03.013","article-title":"Role of bile acids and the biliary HCO(3)(-) umbrella in the pathogenesis of primary biliary cholangitis.","volume":"22","author":"van Niekerk","year":"2018","journal-title":"Clin Liver Dis"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12016-014-8427-x","article-title":"Extrahepatic autoimmune conditions associated with primary biliary cirrhosis.","volume":"48","author":"Floreani","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"R22-20250504","first-page":"643","article-title":"Situation analysis of timing of first visit of anti-mitochondrial antibody-positive patients.","volume":"27","author":"Jin","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.","volume":"28","author":"Chazouill\u00e8res","year":"1998","journal-title":"Hepatology"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue.","volume":"54","author":"Boberg","year":"2011","journal-title":"J Hepatol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bpg.2018.06.003","article-title":"Variant syndromes of primary biliary cholangitis.","volume":"34\u201335","author":"Schulz","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jhep.2009.11.027","article-title":"Primary biliary cirrhosis: a 2010 update.","volume":"52","author":"Poupon","year":"2010","journal-title":"J Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:05:56Z","timestamp":1746335156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":27,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031395","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,11,18]]}}}